Study finds booster shot beats ‘natural immunity’
LOS ANGELES – Public health officials have been struggling to persuade eligible Americans to get their COVID-19 booster shots. New research could help them make the case that the extra dose will provide substantially more protection – even if they’ve also recovered from a coronavirus infection.
A small study that’s among the first to track people’s protective antibodies over time found that those who were immunized against COVID-19 with two doses of an MRNA vaccine and received a booster shot about eight months later saw their levels of neutralizing antibodies skyrocket. Among this group of 33 fully vaccinated and boosted people, the median level of these antibodies was 23 times higher one week after the booster shot than it had been just before the tune-up dose.
What’s more, their median postbooster antibody level was three times higher than was typical for another group of people whose antibodies were measured a few weeks after getting their second dose of vaccine, when they’re close to their peak. And it was 53 times higher than that of a group of 76 unvaccinated people who had recovered from COVID-19 just two to six weeks earlier.
Even compared to a group of 73 people who had weathered a bout with
COVID-19 and went on to get two doses of an MRNA vaccine, the boosted group’s median antibody level was 68% higher.
Study leader Alexis Demonbreun, a cell biologist at Northwestern University’s Feinberg School of Medicine, said the data demonstrates that no matter how well protected vaccinated people may think they are, getting a booster shot is likely to increase their neutralizing antibodies – and with it, their immunity – considerably. And because scientists expect large antibody responses to create more durable immunity, the protection afforded by the booster should last longer than the initial two-shot regimen did.
The study was posted on Medrxiv, a website where researchers share preliminary findings.
The authors measured antibodies that lock onto a key component of the coronavirus spike protein called the receptor-binding domain, which the virus relies on to latch onto a host cell and force its way inside. In tests, they confirmed these antibodies were capable of keeping the virus out of the specific cells it attempts to invade.
While only 33 people were tested before and after getting a booster, their post-boost antibodies were compared to those of 941 people whose levels had been tested already. Everyone who was vaccinated had received one of the MRNA options, made either by Pfizer and Biontech or Moderna.
The resulting group of nearly 1,000 subjects allowed the study’s authors to measure and compare immunity in people who had earned their protection in a variety of ways. (Among their other findings: After receiving two doses of vaccine, people who’d already had an asymptomatic infection were typically no better protected than vaccinated people who had never been infected.)
For the vaccine “passports” used across Europe, people who’ve had a confirmed coronavirus infection are considered immune on a par with fully vaccinated people. Medical and public health leaders there also widely credit a second infection as a booster.